BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase…
Consensus price target: $300.00 (+19636.84% upside from $1.52)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $359.7K | -10.3% | $-14.24M |
| 2024 | $401K | +175.03% | $-8.98M |
| 2023 | $145.8K | +21.7% | $-10.42M |
Stock data for BRTX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics